Repligen Current Ratio 2006-2021 | RGEN

Current and historical current ratio for Repligen (RGEN) from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Repligen current ratio for the three months ending June 30, 2021 was 2.96.
Repligen Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.98B $0.33B 2.96
2021-03-31 $0.93B $0.31B 2.96
2020-12-31 $0.90B $0.32B 2.83
2020-09-30 $0.70B $0.05B 13.67
2020-06-30 $0.69B $0.04B 15.48
2020-03-31 $0.65B $0.04B 15.56
2019-12-31 $0.64B $0.05B 13.29
2019-09-30 $0.62B $0.04B 16.03
2019-06-30 $0.32B $0.14B 2.25
2019-03-31 $0.28B $0.13B 2.18
2018-12-31 $0.28B $0.13B 2.12
2018-09-30 $0.27B $0.13B 2.06
2018-06-30 $0.25B $0.12B 2.09
2018-03-31 $0.25B $0.02B 12.22
2017-12-31 $0.24B $0.03B 9.63
2017-09-30 $0.23B $0.12B 1.95
2017-06-30 $0.20B $0.02B 11.86
2017-03-31 $0.19B $0.01B 13.51
2016-12-31 $0.18B $0.02B 8.74
2016-09-30 $0.22B $0.02B 10.89
2016-06-30 $0.22B $0.02B 10.21
2016-03-31 $0.11B $0.02B 6.65
2015-12-31 $0.10B $0.02B 5.50
2015-09-30 $0.10B $0.02B 6.13
2015-06-30 $0.09B $0.02B 5.89
2015-03-31 $0.08B $0.01B 6.33
2014-12-31 $0.08B $0.01B 7.58
2014-09-30 $0.08B $0.01B 7.23
2014-06-30 $0.07B $0.01B 8.38
2014-03-31 $0.09B $0.01B 12.45
2013-12-31 $0.09B $0.01B 7.64
2013-09-30 $0.09B $0.01B 9.95
2013-06-30 $0.08B $0.01B 7.92
2013-03-31 $0.07B $0.01B 7.95
2012-12-31 $0.07B $0.01B 6.16
2012-09-30 $0.05B $0.01B 5.95
2012-06-30 $0.05B $0.01B 5.38
2012-03-31 $0.05B $0.01B 5.77
2011-12-31 $0.05B $0.01B 6.28
2011-09-30 $0.06B $0.00B 14.45
2011-06-30 $0.05B $0.00B 14.05
2011-03-31 $0.06B $0.01B 12.08
2010-12-31 $0.06B $0.00B 16.43
2010-09-30 $0.06B $0.00B 17.17
2010-06-30 $0.06B $0.00B 17.66
2010-03-31 $0.06B $0.01B 12.82
2009-12-31 $0.06B $0.00B 14.05
2009-09-30 $0.05B $0.00B 12.61
2009-06-30 $0.05B $0.00B 17.11
2009-03-31 $0.06B $0.01B 12.04
2008-12-31 $0.05B $0.00B 14.26
2008-09-30 $0.06B $0.00B 18.31
2008-06-30 $0.05B $0.00B 20.12
2008-03-31 $0.05B $0.01B 11.86
2007-12-31 $0.06B $0.00B 17.97
2007-09-30 $0.06B $0.00B 16.91
2007-06-30 $0.03B $0.00B 7.47
2007-03-31 $0.03B $0.00B 7.71
2006-12-31 $0.02B $0.00B 6.82
2006-09-30 $0.02B $0.00B 8.68
2006-06-30 $0.03B $0.00B 9.11
2006-03-31 $0.02B $0.00B 7.33
2005-12-31 $0.02B $0.00B 6.82
2005-09-30 $0.02B $0.00B 6.66
2005-06-30 $0.02B $0.00B 8.76
2005-03-31 $0.02B $0.00B 5.90
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $15.096B $0.366B
Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUS? series of pre-packed `plug-and-play` chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76